The merger is set to create a company dedicated to gene therapy development for inherited retinal diseases. Credit: elenavolf/Shutterstock. Ocuphire Pharma has announced the acquisition of Opus Genetics to create a biotech company dedicated to gene therapy development for inherited […]
Ocuphire and Opus Genetics merge to develop IRD gene therapy Read More »
SELARSDI, a human monoclonal antibody, targets the p40 protein found in interleukin (IL)-12 and IL-23 cytokines – key in immune-mediated diseases. Credit: BlurryMe/Shutterstock. The US Food and Drug Administration (FDA) has approved a new presentation of Alvotech and Teva Pharmaceuticals’
FDA approves Alvotech and Teva’s SELARSDI for new indications Read More »
VORANIGO, a dual inhibitor of mutant IDH1 and IDH2 enzymes, is designed to penetrate the blood-brain barrier. Credit: CNW Group/Servier Canada. Servier Canada has announced Health Canada’s approval of VORANIGO (vorasidenib tablets) for Grade 2 isocitrate dehydrogenase (IDH)-mutant glioma treatment
VORANIGO approved by Health Canada for IDH-mutant glioma Read More »
The platform targets tumour-specific protease to concentrate potent treatments within the tumour microenvironment. Credit: MUNGKHOOD STUDIO/Shutterstock. Avacta Therapeutics has entered a strategic collaboration with Tempus AI to advance the development of drugs in oncology. Avacta will gain access to Tempus’
Avacta partners Tempus to boost development of cancer therapies Read More »
ATTRv-PN is a progressive disease that causes peripheral nerve damage and motor disability. Credit: Olena Yakobchuk/Shutterstock. The European Union’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AstraZeneca and Ionis Pharmaceuticals’ Wainzua (eplontersen) to treat
EU committee recommends AstraZeneca’s Wainzua for ATTRv-PN Read More »
By integrating patient data with AI/ML technologies, the research team aims to tackle challenging diseases impacting the kidneys and lungs. Credit: mi_viri/Shutterstock. GSK has announced a £50m ($54.3m) investment in a new partnership with the University of Cambridge and Cambridge
Cambridge University and GSK sign immunology collaboration Read More »
In the Phase III STRATUM trial, 80% of patients succeeded in the treatment by week eight using ZORYVE foam. Credit: Arcutis Biotherapeutics, Inc./GlobeNewswire. Arcutis Biotherapeutics‘ subsidiary, Arcutis Canada, has received Health Canada’s approval for ZORYVE (roflumilast) topical foam 0.3%, to
Health Canada approves Arcutis’ ZORYVE for seborrheic dermatitis Read More »
The agreement is intended for the development and manufacture of a cell-based therapy for a diabetic foot ulcer clinical trial. Credit: Olga Apanasenko/Shutterstock. FibroBiologics has entered a master services agreement with Charles River Laboratories to develop and manufacture cell-based therapies
FibroBiologics, Charles River agree on therapies manufacture Read More »
VYLOY is used in conjunction with chemotherapy for the treatment of advanced gastric and gastroesophageal junction cancer. Credit: Emily frost/Shutterstock.com. Astellas Pharma has gained approval from the US Food and Drug Administration (FDA) for VYLOY (zolbetuximab-clzb), in conjunction with chemotherapy,
FDA approves Astellas’ VYLOY for gastric cancer treatment Read More »
Results from Phase III clinical trials have demonstrated that BRENZAVVY significantly lowers haemoglobin A1c and fasting blood sugar levels over 24 weeks. Credit: Dragana Gordic/Shutterstock. TheracosBio has entered a partnership with BAMCO Africa to deliver BRENZAVVY (bexagliflozin), a type 2
TheracosBio to introduce BRENZAVVY in sub-Saharan Africa Read More »
